Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.35 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
| ▸ | AKT2 | P31751 | 2/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2397909 | 0.79 | — | — | |
| SCHEMBL8126732 | 0.79 | CTSD (0.35) | BACE1CTSDKIF11ALDH1A1NOS3 | |
| SCHEMBL8402531 | 0.76 | CTSD (0.36) | BACE1CTSDAKT2KIF11 | |
| SCHEMBL13316010 | 0.75 | LOXL2 (0.33) | NOS3NOS2 | |
| SCHEMBL22543823 | 0.75 | BACE1 (0.38) | BACE1CTSDKIF11TRPV3 | |
| SCHEMBL22543555 | 0.75 | MAP3K12 (0.38) | BACE1CTSD | |
| SCHEMBL14004427 | 0.73 | CTSD (0.35) | BACE1CTSD | |
| SCHEMBL14946763 | 0.73 | DGAT1 (0.33) | AKT2AKT1KIF11 | |
| SCHEMBL2434810 | 0.72 | GRM4 (0.32) | — | |
| SCHEMBL2392610 | 0.72 | HDAC8 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039455-B2 | Macrocyclic compounds useful as BACE inhibitors | NOVARTIS AG (CH) | 2011-10-18 | — | — | US | disclosed |
| US-20100144741-A1 | ETHANOLAMINE DERIVATIVES USEFUL AS BACE INHIBITORS | FREDERIKSEN MATHIAS | 2010-06-10 | — | — | US | disclosed |
| US-20090312370-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2009-12-17 | — | — | US | disclosed |
| CN-101528670-A | 2-hydroxy-1, 3-diaminopropane derivatives | NOVARTIS AG (CH) | 2009-09-09 | — | — | CN | disclosed |
| EP-2094645-A1 | 2-HYDROXY-1,3-DIAMINOPROPANE DERIVATIVES | Novartis AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| US-20090170878-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2009-07-02 | — | — | US | disclosed |
| EP-2046760-A1 | MACROCYCLIC LACTAMS | Novartis AG (CH) | 2009-04-15 | — | — | EP | disclosed |
| EP-2046761-A2 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | Novartis AG (CH) | 2009-04-15 | — | — | EP | disclosed |
| US-20090029960-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BASE INHIBITORS | NOVARTIS AG (CH) | 2009-01-29 | — | — | US | disclosed |
| EP-1968954-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | Novartis AG (CH) | 2008-09-17 | — | — | EP | disclosed |
| WO-2008062044-A1 | 2-HYDROXY-1,3-DIAMINOPROPANE DERIVATIVES | NOVARTIS AG (CH) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008009734-A1 | MACROCYCLIC LACTAMS | NOVARTIS AG (CH) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008009750-A2 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2008-01-24 | — | — | WO | disclosed |
| WO-2007077004-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312370-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | BACE2, BACE1, APP | BACE1 2/4885CTSD 16/4885AKT2 2391/4885 |
| US-20090029960-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BASE INHIBITORS | SLC10A2, SLC10A1, ASAH2 | BACE1 2477/4885CTSD 557/4885AKT2 3539/4885 |
| US-20100144741-A1 | ETHANOLAMINE DERIVATIVES USEFUL AS BACE INHIBITORS | BACE1, BACE2, APP | BACE1 1/4885CTSD 119/4885AKT2 1914/4885 |
| US-20090170878-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | BACE2, BACE1, APP | BACE1 2/4885CTSD 16/4885AKT2 2391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.